Compare Invesco WilderHill Clean Energy ETF (PBW) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco WilderHill Clean Energy ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Invesco WilderHill Clean Energy ETF trades at $33.85, while State Street SPDR S&P Biotech ETF trades at $152.06. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Invesco WilderHill Clean Energy ETF nearer its low. Which is the better fit depends on your goals.
| PBW | XBI | |
|---|---|---|
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $46.99 | $164.28 |
52-Week Low | $22.23 | $85.16 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PBW trades at $33.21, down 0.54% today, amid a bearish technical signal with moving averages indicating strong selling pressure. The ETF shows oversold conditions on short-term RSI readings but faces headwinds from sector volatility. Recent news highlights clean energy's potential tailwinds from energy security concerns and data center demand, though the fund remains sensitive to interest rate movements and semiconductor market swings.
The outlook for PBW is cautious; while clean energy thematic demand provides long-term opportunity, near-term risks include interest rate sensitivity and tech sector correlation. Investors face volatility from macroeconomic factors and sector-specific pressures, requiring careful risk assessment amid mixed technical and fundamental signals.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco WilderHill Clean Energy ETF
PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.
Read more on PBW →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
